Annual revenues reached €10,225K in 2021, up 20.9% compared to 2020 (€8,456K) following the invoicing of services provided for in Merck and Novo Nordisk contracts.
Ascensia Diabetes Care, a global diabetes care company, announces that it has launched the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System for patients in the U.S., alongside the new Eversense PASS savings program.
#cgm
Embecta comes in with a wealth of experience, according to former Worldwide President of BD Diabetes Care and new Embecta CEO Devdatt Kurdikar, who spoke with Drug Delivery Business News following the spinoff’s completion on April 1.
Lark Health announced it has launched Lark for Salesforce on Salesforce AppExchange, empowering customers to simplify care management for health plans and their members with enhanced technology, providing a simple and digestible way for members to engage in their care.
Better Therapeutics, Inc. (NASDAQ: BTTX), today announced several key research milestones designed to advance and further validate its therapeutic technologies, including the first ever study of nCBT as potential treatment for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). This announcement arrives on the heels of positive primary endpoint data from the pivotal clinical trial of BT-001, the company’s prescription digital therapeutic for type 2 diabetes.
#dtx
The report provides the overall revenue of the global continuous glucose monitoring market for the period 2017-2028, considering 2020 as the base year and 2028 as the forecast year.
HAGAR, the developer of GWave, the world's first non-invasive continuous glucose monitoring technology, will present data from two of its completed clinical studies at the upcoming 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) to be held in Barcelona and online from April 27 to 30.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report financial results for its second quarter of fiscal year 2022 on Thursday, May 5, 2022.
The insulin pens market is expected to grow at a CAGR of 6.26% during the forecast period.
#insulin pen
Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor. Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months (180 days).
#cgm